This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Baylor College of Medicine. Active years: 2005-2008.
Company Filing History:
Years Active: 2005-2008
Title: Innovations by Hugo Bellen
Introduction
Hugo Bellen is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of therapeutic applications, particularly in relation to deafness, osteoarthritis, and abnormal cell proliferation. With a total of 4 patents to his name, Bellen's work is recognized for its potential impact on medical science.
Latest Patents
One of Bellen's latest patents focuses on the composition and methods for the therapeutic use of an atonal-associated sequence for various medical conditions. This patent discloses compositions and methods that utilize an atonal-associated nucleic acid or amino acid sequence. Additionally, it describes an animal model heterozygous for an atonal-associated gene inactivation, which has at least one atonal-associated nucleic acid sequence replaced by a heterologous nucleic acid sequence. This model is used to detect expression driven by an atonal-associated promoter sequence, where the inactivation of the atonal-associated nucleic acid sequence prevents the expression of the atonal-associated gene.
Career Highlights
Hugo Bellen is affiliated with the Baylor College of Medicine, where he continues to advance his research and innovations. His work is characterized by a commitment to exploring the therapeutic potentials of genetic sequences, which could lead to groundbreaking treatments for various health conditions.
Collaborations
Bellen collaborates with notable colleagues such as Bassem Hassan and Nessan Bermingham. Their combined expertise contributes to the innovative research being conducted at Baylor College of Medicine.
Conclusion
Hugo Bellen's contributions to the field of medical science through his patents and research at Baylor College of Medicine highlight the importance of innovation in addressing complex health issues. His work continues to pave the way for future advancements in therapeutic applications.